Concentric Medical Science and Technology Innovation Board IPO accepted for review

According to the official website of the Shanghai Stock Exchange, recently, Suzhou Tongxin Medical Technology Co., Ltd.'s application for an IPO on the Science and Technology Innovation Board has been accepted. In this IPO, the company plans to raise 1.064 billion yuan to be used for the construction of a production base for implantable left ventricular assist systems, the global clinical trial and registration project for the BrioVAD implantable left ventricular assist system, the research and development project for the next generation LVAS, and to supplement working capital.